The Application of High-Throughput Technologies for the Study of Microbiome and Cancer



Human gut microbiome research, especially gut microbiome, has been developing at a considerable pace over the last decades, driven by a rapid technological advancement. The emergence of high-throughput technologies, such as genomics, transcriptomics, and others, has afforded the generation of large volumes of data, and in relation to specific pathologies such as different cancer types. The current review identifies high-throughput technologies as they have been implemented in the study of microbiome and cancer. Four main thematic areas have emerged: the characterization of microbial diversity and composition, microbial functional analyses, biomarker prediction, and, lastly, potential therapeutic applications. The majority of studies identified focus on the microbiome diversity characterization, which is reaching technological maturity, while the remaining three thematic areas could be described as emerging.

Human microbiome research has been developing at a considerable pace over the last two decades, partly driven by technological advancement and the ability for high-throughput, culture-independent analyses, and in part because the ability to analyze and interpret the increasing quantities of data has now become possible. As in any rapidly evolving field, there can emerge differences in the definition. For the purposes of this study, which focuses on the human microbiome, especially gut microbiome, the term microbiome aligns with previously reported ones and refers to the entire habitat view, including the microorganisms, their genomes, and associated clinical metadata (Marchesi and Ravel, 2015).

Beyond these early historical examples, the current era of laboratory automation has ushered-omics technologies, which are increasingly high-throughput, allowing for the detailed characterization of collected samples and specimens from patients and healthy individuals alike. Still, the efforts are mostly concentrating on the accurate characterization of the diversity of the microbiome (and its progressive changes over time in the case of sequential sampling), leading to the interpretation of these observations. While interventions have started taking place (DeFilipp et al., 2018; Smibert et al., 2019; Wing and Kremenchutzky, 2019), these are at the initial stages and not yet an established clinical practice. It is anticipated that the increased understanding in this field through high-throughput laboratory methodologies will lead to future interventions, as well as preventive actions in relation to cancer development. Previous reviews have summarized high-throughput sequencing technologies and the platforms used (Reuter et al., 2015), reviewed shotgun metagenomics process in detail (Quince et al., 2017) or its application in microbiome and several diseases (Wang and Jia, 2016), discussed the gut microbiome (virome) in health or disease situation (Carding et al., 2017), or reviewed investigations on microbiome and cancer (Contreras et al., 2016; Helmink et al., 2019). Notwithstanding the above, the current manuscript is a systematic review on the subject of the high-throughput methodologies that have been employed over the last two decades in the study of the human gut microbiome in relation to cancer. It provides a useful benchmark on current technological developments, biological interpretations, and how the latter might eventually influence clinical practice.

The systematic review followed the PRISMA guidelines (Figure 1) (Stewart et al., 2015). Two investigators (LW and GY) independently conducted literature search using as combined keywords microbiome and cancer, security on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and Web of Science (v. 5.35). The database search was run of all the published articles, all languages, from database inception until March 1, 2021. In both databases, the following search strategy was used: terms were searched as follows: Microbiome AND Cancer AND *omics; Microbiome AND Cancer AND high-throughput; Microbiome AND Cancer AND genomics/metabolomics. *omics was used in the search in order to identify longer forms. It is thought that these terms would be able to identify the majority of manuscripts within a narrow definition of microbiome and cancer and applied omics methodologies, though it remains likely that relevant sections might be embedded within methodology sections of particular projects and thus more challenging to identify.

All studies reporting information on microbiome, cancer, high-throughput, and -omics were included. A total of 962 articles were identified and reviewed independently by two authors (LW and GY), and after all duplicates were removed, 673 articles were considered. After removing articles that were not in English, and those that had simply a mention of the words with no further expansion, 127 articles were considered. These articles are included in Table 1 for transparency and further reference. One hundred twenty-one articles (of the 127) devoted considerable amount of the manuscript to expand on those topics, while 6 articles had much reduced and/or incomplete analyses. Both of these latter categories were used in the current review. Any inconsistencies were resolved by consensus with a third author (ZK), while thematic groupings (Table 2) and analyses were reviewed by an additional author (IC). All outcomes were included, due to the wide range of use of the terminologies.

The manuscripts identified in this review (n = 121) followed four loosely defined thematic groups: (a) the methods used in measuring diversity (n = 121, i.e., all of the manuscripts used in this systematic review contained an element of measuring microbiome diversity), (b) the microbial functional analyses (n = 19), (c) the biomarker predictions (n = 19), and (d) microbiome in relation to cancer therapy (n = 30). They will be presented subsequently in this order, reflecting the scientific continuum, moving from the characterization and acquisition of knowledge, to the interpretation and finally toward clinical implementation. It becomes clear that both the number of technologies applied as well as the number of publications are increasing consistently, especially in the last few years, as can also be evidenced by the information on Table 2, and Table 1, with some studies deploying more than one methods in parallel. The most frequently used high-throughput technologies include in relative order of frequency amplicon sequencing, metagenomics, meta-transcriptomics, proteomics, and metabolomics. All of the above are accompanied with references, sometimes extensive, on continuously advancing bioinformatics analytical methods.

Diversity characterizing of the microbiome nowadays depends largely on cultivation-independent molecular technologies (Su et al., 2012) due to the unculturable property of the majority of microbes consisting the microbiome (Stewart, 2012; Browne et al., 2016). The sequential development of tools [including PCR-denaturing gradient gel electrophoresis (DGGE) (Scanlan and Marchesi, 2008; Zhang et al., 2010), fluorescence in situ hybridization (FISH) (Fredricks et al., 2005), quantitative dot blot hybridization, restriction fragment length polymorphism (RFLP) (Laguerre et al., 1994), terminal restriction fragment length polymorphisms (T-RFLP) (Wang et al., 2009), clone library (Bik et al., 2010; Rehman et al., 2011), and gene chip (Luo et al., 2020)] and the emergence of high-throughput sequencing technologies [16S/18S rRNA/rDNA gene sequence analysis (Fredricks et al., 2005; Scanlan and Marchesi, 2008; Rehman et al., 2011), high-throughput pyrosequencing (Rehman et al., 2011), metagenomics, meta-transcriptomics, and single-cell genomics (Lasken, 2007; Ishoey et al., 2008)] have broadened the perception of microbial diversity and evolutionary relationships of microbiota (Pace, 1997).

Advantages and limitations of major high-throughput technologies are shown in Table 3. The integration of such multi-omic methodologies can provide further insights into cancer research (Liu Y.-X. et al., 2020). For example, Peters et al. (2019) characterized the gut microbiome for melanoma patients by 16S rRNA gene and shotgun metagenome sequencing and pointed out that the clustering of patients based on 16S microbiome composition was slightly more predictive of progression-free survival than clusters based on shotgun microbiome composition; on the other hand, species-level classification was much higher in the shotgun data, permitting researchers to identify more response-associated species than with 16S data alone.

The application of high-throughput methodologies to the study of the human gut microbiome focuses not only on the microbiome composition but also on the functional analysis of the identified microbiome. Amplicon sequencing is a commonly used key tool for studying microbial communities as discussed above. The application of 16S rDNA (Dubin et al., 2019) or ITS rDNA using ASVs in DADA2 pipeline detected microbiome community in a high-resolution and high-accuracy way, which also helps identify the cross-kingdom dysbiosis and demonstrate the expansion and translocation pattern of pathogenic fungi during disease progression (Zhai et al., 2020). In addition, amplicon sequencing can also provide predictive functional analyses of microbial communities with quantifiable uncertainty if combined with advanced computational algorithms. PICRUSt was developed for predicting metagenomes according to amplicon sequencing data and reference genome databases (Langille et al., 2013). For example, QIIME and PICRUSt were utilized for diversity and compositional analysis and functional prediction after 16S rRNA sequencing, and it showed that proinflammatory pathways, such as lipopolysaccharide biosynthesis and peptidases, were enriched in the oral squamous cell carcinoma tissues and provided evidence for the inflammatory characteristic of bacteria related to cancer (Perera et al., 2018).

Additionally, different from the mRNA-based analyzing of meta-transcriptomics, meta-proteomics and metabolome are also new post-genomics high-throughput omics technologies for characterization of the whole protein component and all metabolites of microbiome at any given moment. They reveal the structuralâ€“functional diversity and dynamic changes at the protein level and metabolite level of microbes, which serves as potential biomarkers and enables an in-depth understanding of metabolic changes of microbial communities under diverse habitats (Johnson et al., 2016; Wilmanski et al., 2019; Dubey et al., 2020). The combination of metagenome and metabolome helped researchers to distinguish unique stage-specific phenotypes of the gut microbiota in CRC at the levels of species, genes, metabolic pathways, and metabolites (Yachida et al., 2019).

The number of microbes associated with the human body is estimated as at least 10 times that of human cells (Sender et al., 2016). Thus, initial investigations into microbes in cancer, such as the association between H. pylori and MALT lymphoma (Stolte, 1992), mainly focused on discovery, culture, and identification when they first emerged (Gilbert et al., 2016) using established and well-validated methodologies. Moreover, the characterization of microbiome in tumor remains challenging due to the low biomass of microbiota and methodological limitations (Nejman et al., 2020). Most microbiota was broadly considered as unculturable because of its tremendous genetic and biochemical diversity and the difficulties to mimic the natural living conditions in the laboratory (Stewart, 2012; Browne et al., 2016). High-throughput omics analyses are no longer limited to just detecting a few strains, but can detect microbiome in different microbiome niches in various cancer types (Nejman et al., 2020), thus providing a more comprehensive picture of the microbiome in relation to tumor development.

For example, such an analysis was performed in 1,526 samples from seven different types of solid tumors by applying a combination of methods including electron microscopy, H&E staining, immunohistochemistry (IHC), 16S rRNA FISH, qPCR, and culture ex vivo, coupled with high-throughput 16S rDNA sequencing (Nejman et al., 2020). This validated distinct microbial distributions in different tumor types and even across different subtypes of the same tumor type, which was also associated with bacterial prevalence and metabolic functions (Nejman et al., 2020). Accordingly, well-defined microbiome constituents can serve as a potential screen for early-stage cancer (Zackular et al., 2014) or a biomarker for prediction of cancer progression (Li et al., 2020). Re-analysis of raw 16S rRNA gene sequence data sets from nine separate studies in conjunction with a detailed meta-analysis and machine learning identified a composite microbial biomarker for diagnosing CRC consistent across studies (Shah et al., 2018). However, the low taxonomical and functional resolution of 16S rRNA sequencing limited the interpretation of the results beyond the accurate reach of species level (Shah et al., 2018). Multi-cohort metagenomic profiling studies highlighted and validated the potential of fecal metagenomic biomarkers for early non-invasive diagnosis of CRC even in different populations with distinct intestinal microbial community (Yu J. et al., 2017; Dai et al., 2018). The dynamic changes of microbial composition, gene abundance, and metabolites in gut microflora during the progression of CRC revealed by metagenomic and metabolomic analysis in a large cohort indicated microbial and metabolic shifts in the very early stages of CRC, which may contribute to a routine etiological diagnosis in the future (Yachida et al., 2019).

Besides the correlation of microbiome and cancer development, the same suite of methodologies is starting to be applied in order to characterize the therapeutic sensitivity or resistance to the treatment(s) of cancer(s). They can also contribute to discovering specific microbiota that influence the curative effects. For example, to examine the potential relationship between altered intestinal flora, CRC recurrence, and chemoresistance, investigators performed pyrophosphate sequencing and found that Fusobacterium nucleatum enriched in the CRC recurrent group promoted CRC chemoresistance via activating the cancer autophagy pathway (Yu T. et al., 2017).

Application of sequencing-based high-throughput technologies enabled the scientists to observe the microbial dysbiosis at an integrated scale (Dong et al., 2018; Gopalakrishnan et al., 2018). In such a case, the microbiome and prognosis of allogeneic hematopoietic cell transplantation was investigated via 16S rRNA gene sequencing (Peled et al., 2020). The results demonstrated that higher microbial diversity during the transplantation period was associated with a reduced risk of death and increased overall survival, which can potentially be used as a biomarker to predict mortality in allogeneic hematopoietic cell transplantation patients (Peled et al., 2020). Notably, 16S rRNA gene and metagenomic sequencing of fecal samples in a phase I clinical trial suggested that performing fecal microbiota transplantation (FMT) treatment was associated with favorable changes in immune cell infiltration and gene expression profiles in the intestinal lamina propria and tumor microenvironment (Baruch et al., 2021). Overall, the integration of NGS methodologies with clinical analyses and treatment allowed one to observe the dynamic changes of gut microbiome and adjust the choice of treatment on tumor in time (Tanoue et al., 2019; Zheng et al., 2019; Erawijantari et al., 2020).

This manuscript is a systematic review of the application of high-throughput technologies to investigate both the microbiome and cancer. It is important to note that the studies identified in this review, using these high-throughput technologies, tend to focus more on characterizing the diversity of the microbiome as a whole and in cancer in particular. The large data volumes generated through -omics applications, e.g., genomics, metagenomics, and meta-transcriptomics, are frequently applied to the purposes of taxonomic composition profiling, functional annotation, and pathway enrichment analyses through computational approaches. This increasing application of omics enables also a better look into the dynamic changes and functional features of microbial communities under specific habitats, and for specific patient groups. As was evident by a number of identified publications, the latter analyses can also provide evidence for potential biomarkers or predictors for disease detection.

Notwithstanding the above, the current review has some limitations. Specifically, the search included manuscripts that were identified in two online databases (PubMed and Web of Science) with parameters including year/language type/article type/keywords. This might have limited the breadth of the results. Additionally, pre-print databases, such as bioArxiv and F1000, were excluded as those manuscripts have not completed a peer-review process. In a field that is actively growing, such as the application of high-throughput technologies on microbiome and cancer, this strategy may lead to the omissions of the newest technologies currently under development. Furthermore, this review focuses on the application of these technologies without comparing potential integrating methodologies that may offer an additional layer of complexity.

The emergence of high-throughput technologies enables in-depth studies on the relationship between microbiome and cancer. The ability to profile the microbiome as a whole, as well as the complex micro-ecosystems of the microbiome, enhances the possibility to use/measure specific microbial strata as predictive markers of cancer and eventually perhaps as a guide for precise treatments. However, these high-throughput methodologies produce high volumes of data and, as such, a downstream pressure for bioinformatics component able to ingest and interpret the results. Additionally, there still exist technical detection limits, especially with processing low-biomass samples.

Having said that, the majority of identified manuscripts in this review are still focusing their efforts on characterizing the microbiome and its relationship with cancer in detail. The many mechanisms by which the microbiome has the potential to modulate cancer development provide the possibility to target the microbiome for cancer prevention strategies. Additional clinically relevant data need to be generated, before microbiota-based strategies for cancer prevention can be envisioned and integrated into routine healthcare.

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

LW and GY conducted the systematic review and applied the eligibility selection criteria for the identified manuscripts. IC and ZK validated the selected manuscripts and arbitrated any queries. LW, GY, IC, and XL wrote the manuscript. NL, LD, and HW oversaw the process and provided critical input throughout. All authors were involved in the drafting of the manuscript.

Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/WHO.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding. This study was supported by grants from the National Key R&D Program of China (2018YFC2000700), the National Natural Science Foundation (82030099 and 81630086), Shanghai Public Health System Construction Three-Year Action Plan (GWV-10.1-XK15), the Major Science and Technology Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00059), and Innovative research team of high-level local universities in Shanghai.

